Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DYAI was written up on the microcapclub.
Yahoo-live with Mark
https://finance.yahoo.com/video/really-shame-pandemic-government-didn-213303398.html
Sorrento just created a $5B shelf. That would more than do it. That started the rumor.
SRNE could not afford them
Where did you see that?
Any truth to the rumor that Sorrento is buying DYADIC?
Only a few more workdays in 2021. Wonder if Sorrento will ink the deal before the end of the year? Wonder what that deal is.
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
https://finance.yahoo.com/news/dyadic-announces-niimbl-coronavirus-grant-141200810.html
Under the NIIMBL grant, Dyadic will receive up to $690,000 in funding to engineer the Company’s proprietary and patented C1 thermophilic fungal (Thermothelomyces heterothallica) protein production platform to produce two different antibodies.
Research, License, and Collaboration Agreement with Janssen
https://finance.yahoo.com/news/dyai-jumpin-janssen-jamboree-092200577.html
Tue, December 21, 2021, 4:22 AM
In this article:
By John Vandermosten, CFA
NASDAQ:DYAI
READ THE DYAI RESEARCH REPORT
Research, License, and Collaboration Agreement with Janssen
On December 17, 2021, Dyadic International Inc. (NASDAQ:DYAI) released news that the company had entered into a research, license, and collaboration agreement with Janssen Biotech, Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ). The agreement was facilitated by Johnson & Johnson Innovation. Details of the structure of the Janssen agreement are provided in Dyadic’s latest 8-K; however, parameter specifics, including strategic targets and payment amounts, have been redacted. According to the provided exhibit, the therapeutic proteins that Dyadic is helping Janssen to produce are likely monoclonal antibodies, which was mentioned in the addendum to the 8-K that Dyadic supplied to the SEC. The antibody target(s), however, remain undisclosed, but the partnership is a testament to the abilities for Dyadic’s C1, fungal-based technology, to produce complex therapeutic proteins.
Under the terms of the agreement:
? Dyadic will receive an upfront payment of $500,000 for non-exclusive rights to utilize the C1 platform to develop C1 production cell lines for the manufacturing of Janssen's therapeutic protein candidates against several biologic targets;
? Janssen will provide R&D funding of up to $1.8 million1 to develop and assess C1 production cell lines for its candidates;
? Janssen has option to pay mid-seven figure payment for exclusive license to use C1 for manufacturing of therapeutic proteins directed to a single, specific target;[/quote]
Think Sorrento will sign on the dotted line or walk? Never be afraid to walk away from a deal.
HC Wainwright initiates a buy recommendation with $7 price target.
I want a hat trick
many shots on goal. 1st score
https://finance.yahoo.com/news/dyadic-announces-research-license-collaboration-120000301.html
Bangladesh here we come
Patrick Lucy: https://twitter.com/PatrickKLucy
Board Member
$DYAI Pamp it
Yeap, added yesterday
Wall street shorting right into our lap
I'll pay for a dance like this everyday..
that's pretty much how i see it.
Sometimes when one breaks ranks then the others rush to follow for fear of being left behind.
No one wants to take the risk of being the first...maybe? Donno
I dont get it as well.
For 1bn the could buy a compelling technology - and not only for pharm purposes
With these obvious advantages, what keeps it from being adopted. Outside of big pharma's vested interests to protect. What is the downside of adopting and using the C1 platform?
Wow, the company anticipates stable Omicron antigen in two months after gene synthesis.
The hell with SRNE...who needs them?
If it is a Vaccine a better manufacturing process could possibly produce fewer elements that could cause undesirable reactions.
The main feature with C1 is a higher yield with less cost. Couple that with a delivery system such as the Sorrento Therapeutics SOFUSA LYMPHATIC DELIVERY SYSTEM which can lower the dose to 10% needed by an IV delivery and that can drive the retail product cost down and widen the available market considerably.
Any thoughts on how the manufacturing process impacts a drugs effectiveness?
Yes, Big ego's involved here.
Agreement isn't cancelled it was extended as Sorrento wants to enlarge it possibly to other processes and subsidiaries such as Ark Animal Health which is a wholly owned subsidiary of Sorrento.
I did not hear the fat lady sing yet.
Still in the works. Technology transfer is on going while they work on a larger deal.
There is the manufacturing of Vaccines with Dyadic technology that is being transferred to Sorrento already and a larger deal being discussed. Higher throughput in less space at lower cost with Sofusa technology opens up the gateway to servicing not only the wealthy countries but also the underserved regions of the world which is the goal of both companies and of course they want to make money while doing this; Lower cost higher volume Japanese model.
Thanks for report.
50/50 SRNE goes the distance. If it collapses we are left with nothing in the near/mid-term for incoming cash/sales. An upcoming 'collaboration' means little. Sanofi yielded nothing at the end of years of collaboration. Look out below if the SRNE deal is gone. OTOH, if SRNE moves ahead, we could easily double back to $7. A crapshoot. Mark's demeanor suggested that he believes its a crapshoot as well.
not sure that SRNE has fallen apart yet, but it is being reworked currently.
new ZACKS report
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_11112021_DYAI_Vandermosten.pdf
Nails are not in the coffin yet... May never know why it fell apart. But, it appears that SRNE CEO may be a bit of a sleazeball. Unfortunate that Mark can't attract better partners. He has a very poor record so far.
Did Mark ever say why? What was the reason for cancelling the agreement? The devil is in the detail. Over promise and under deliver?
The most encouraging part of the cc was the addition of the new hire. Otherwise, Mark seemed very tired, and seemed to have lost a step or two. I think the SRNE blow was a very significant loss, and will be challenging to properly address and overcome....assuming the deal is dead.
Good conference call last, it's a shame no one believes him
stock is up.
someone is Bangladesh placed an order?
Nice find...Bangladesh?!?! Could he find a more questionable country? Maybe Somlia is next.. It sounds like this company doesn't have the wherewithall to produce an aspirin never mind a complex product. Concrete takes too long to use in the site's development so they are using steel. What could possibly go wrong in an area with regular 200 MPH typhoons. Lord, we are scraping the bottom of so many barrels. Sounds like DYAI will be on the hook to get the plant built, running, etc, and probably funding a good part of it. DYAI is smart not to put out a PR at this time.
Covid vaccine to be produced locally with a US formula
Vaccine production might start within next six months
Photo: Courtesy
Photo: Courtesy
Highlights:
The vaccine will be produced by state-owned Essential Drugs
Vaccine production might start within next six months
MoU will be signed with Dyadic International over transfer of raw materials and technology for producing vaccine
Technical committee on vaccine production has recommended allowing Dyadic to conduct clinical trials in the country
Appointments of consultant and scientist are in process
The government is planning to produce a coronavirus vaccine in the country through transfer of technology, using the formula invented by the US-based company Dyadic International.
Necessary steps are being taken to produce this vaccine at Essential Drugs Company Limited (EDCL), a state-owned drug manufacturing company in Gopalganj.
Initiatives are underway for a memorandum of understanding (MoU) to be signed in order to come by Dyadic's formula and technology, to set up vaccine plants in steel structures and to expedite the process of land acquisition.
If everything goes according to plan, the country might start producing protein vaccines within the next six months.
Professor ABM Khurshid Alam, convener of the Technical Committee on Vaccine Production and Director General of the Directorate General of Health Services (DGHS) told The Business Standard, "Negotiations are underway with the American company Dyadic. If they agree to transfer the technology, the vaccine will be produced in the country. If not, the vaccine will be brought in bulk and finished here."
The US biotechnology firm Dyadic International has already joined the race to produce Covid-19 vaccines in Africa, the least-vaccinated continent.
The company announced in July this year a technology transfer and licensing deal with South Africa's Rubic Consortium. Permission will be sought for the Covid-19 vaccine trial this year, according to a Bloomberg report.
Essential Drugs Company has meanwhile held several meetings with Dyadic International.
The government initially bought the Oxford University-developed AstraZeneca vaccine, which was supposed to be obtained from the Serum Institute of India. But, after supplying several consignments, India stopped exporting the vaccine due to increased corona infections within its territory. Then the Bangladesh government bought Pfizer, Moderna and Sinopharm vaccines from alternative sources.
An MoU will be signed with Dyadic over the transfer of raw materials and technology for producing vaccines in the country. A draft MoU has already been prepared. The MoU will be signed after getting government approval.
Professor Dr Ehsanul Kabir Jaglul, managing director of Essential Drugs Company Limited, said, "Dyadic International wants to sign an MoU. It will be signed after getting permission from the committee formed by the health ministry. Work on the signing of the MoU is in progress. If it is not signed, there is a risk that they will go elsewhere."
In addition to Dyadic, discussions are underway to produce protein vaccine invented by Russia's Sputnik-V and Oxford University, according to a meeting of the Parliamentary Standing Committee on Health and Family Welfare held on 13 October.
At the meeting, it was recommended that necessary steps be taken for the rapid production of vaccines in the country.
The meeting was informed that on the advice of experts, the main equipment for making corona vaccine will be imported from Europe, America and Japan while other equipment will be imported from various Asian countries, including China, South Korea and Taiwan.
An estimated cost relating to the imports has also been set by contacting various foreign equipment manufacturing and supplier organisations.
Technical committee on vaccine production and its recommendations
The government formed a nine-member Covid-19 Resistant Vaccine Production Technical Committee on 12 July this year, to make recommendations to the government by reviewing proposals and taking steps to produce effective and safe vaccines.
After holding five meetings since its formation, the committee put forward various recommendations for vaccine production.
According to committee sources, the technical committee has recommended that trials be allowed in the country to determine the efficacy and side effects of the vaccine invented by Dyadic International since Dyadic invented the formula but could not complete the trial. If the trial is allowed on the condition that the vaccine will be produced in Bangladesh, it can be produced as soon as possible. The committee recommended allowing the trial because formulas of the corona vaccines invented so far are not easily available.
Committee sources said there is also a shortage of raw materials of vaccine due to the widespread global demand for the corona vaccine. However, there will not be any shortage of raw materials for the production of Dyadic protein vaccines.
Dr Abdur Rahman, a member of the technical committee and dean of the Faculty of Pharmacy of Dhaka University, told TBS that it has been recommended that Dyadic be allowed to conduct clinical trials in the country; in return it will assist in setting up a vaccine plant and provide vaccine formula.
He said, "If this is done, we will get the vaccine formula in a short time and they will also get an advantage. The protein vaccine has a big advantage as there will be no shortage of raw materials for it. However, there is a shortage of raw materials for other vaccines due to the global demand."
Infrastructure development of Essential Drugs
Although the government has taken the initiative to produce vaccines by the state-owned Essential Drugs Company, it does not have adequate and necessary infrastructure.
It was established in 1983 with the main objective of setting up an advanced pharmaceuticals industry in the country to produce medicines.
But this outdated pharmaceutical company does not have the necessary equipment and modern laboratory to produce corona vaccines. It is not possible to produce corona vaccines with its existing infrastructure.
However, the government's emphasis on vaccine production has removed the complexity of infrastructure development.
As the construction of a concrete building is time consuming, it has been decided to construct the building within a steel structure.
For the building eight acres of land have been acquired next to Essential Drugs Company. The steel structure will be built on the land to accommodate the necessary labs and equipment for vaccine production.
As per recommendations of experts, the vaccine will be stored in a cold room and cool room of the manufacturing plant at a temperature of 2-8 degrees centigrade.
Professor ABM Khurshid Alam said, "Ninety percent of the land has been acquired for the construction of the vaccine plant and the remaining 10% will be acquired this month."
"A steel structure will be built there to go into production as soon as possible. The appointments of a consultant and a scientist are in the process," he added
https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-vaccine-be-produced-locally-us-formula-318403
Lot of eggs in this SRNE basket. 20% drop in response to the lack of closure....and possibly a lot more to come. Maybe SRNE realizes they've got Mark over a barrel and pushing for much better terms. Why not. This partnership is Mark's 1 trick pony, and the other guy has the reigns. Always a drama with this company. What happened to animal health?
nope, just more tick tock. Let's see if they can close a deal
Paulee,
Got any thoughts on this? From an 8K released yesterday.
Thanks, sounds like the right partnership
Benzinga Conference
scroll over to the 3:13 (3 hours and 13 minutes) timeframe to Dyadic’s presentation
When the panel discussion starts scroll over to the 3:47:30 timeframe..Sorrento CEO relationship w/Dyadic/expectations...listen to what Mark Emalfarb has to say.
Thx, yeah tailwinds use to follow DYAI. Dropped coverage a while back.
Tailwinds Research is the public site, but then you pay membership for the chat room and zoom sessions. They had DYAI in their portfolio but dropped them. TFFP is a key piece of their portfolio.
care to share the chatboard info, or is it an invite only? I can't quite get my head around where their fungus system would work with an inhalable ?
Pretty clear what they'd be working on with TFFP (inhalable vaccine delivery). Possibly SRNE is a part of that puzzle, or maybe not..Emelfarb might as well go for a brass ring for break-through production AND delivery systems for Africa, etc.
Otherwise, I'm a fly on the wall, as the chat guys are ex-Wall Street, clubby, and in a different pay grade where I would not intrude...so I'm not asking questions there, just picking up bits of insights.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1155
|
Created
|
10/19/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |